clinical trial · NCT02537431
Open Label Study of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH)
Kyowa Kirin, Inc.·phase3·completed·n = 14
X-linked Hypophosphatemiaburosumab
brief summary
The primary objective of this study is to establish the effect of KRN23 treatment on improvement in XLH-associated osteomalacia as determined by osteoid volume (osteoid volume/bone volume, OV/BV).
started
Dec 23, 2015
primary completion
Aug 30, 2017
completion
Dec 13, 2018
last updated
Jun 18, 2024
official title
An Open-Label, Single-Arm, Phase 3 Study to Evaluate the Effects of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol